Download PDF
Klin Padiatr 2023; 235(06): 342-349
DOI: 10.1055/a-2146-1395
Übersicht

Therapiestrategien bei Kindern und Jugendlichen mit Langerhanszell Histiozytosen

Therapeutic Strategies In Children And Adolescents With Langerhans Cell Histiocytosis
Anke Elisabeth Barnbrock
1   Pädiatrische Hämatologie, Onkologie und Hämostaeologie, Klinik für Kinder- und Jugendmedizin, Goethe-Universität, Frankfurt, Germany
,
Caroline Hutter
2   Children’s Cancer Research Institute, St Anna Kinderkrebsforschung, Medizinische Universität Wien, Wien, Austria
,
Konrad Bochennek
1   Pädiatrische Hämatologie, Onkologie und Hämostaeologie, Klinik für Kinder- und Jugendmedizin, Goethe-Universität, Frankfurt, Germany
,
Milen Minkov
2   Children’s Cancer Research Institute, St Anna Kinderkrebsforschung, Medizinische Universität Wien, Wien, Austria
,
Thomas Lehrnbecher
1   Pädiatrische Hämatologie, Onkologie und Hämostaeologie, Klinik für Kinder- und Jugendmedizin, Goethe-Universität, Frankfurt, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Die derzeitige Standardtherapie bei Kindern und Jugendlichen mit neu diagnostizierter Langerhanszell Histiozytose (LCH) beruht auf den Medikamenten Prednison und Vinblastin. Im Falle eines schlechten Therapieansprechens bzw. Reaktivierung hängt das weitere Vorgehen von Faktoren wie zum Beispiel des Befalls eines Risikoorgans wie Leber, Milz oder hämatopoetisches System ab. Der folgende Artikel gibt eine Übersicht über die wichtigsten aktuellen Daten zu Therapieoptionen in den unterschiedlichen klinischen Situationen, die aufgrund der fehlenden Evidenz meist nicht ausführlich in den aktualisierten Leitlinien dargestellt werden. Auch werden neue Therapieoptionen wie Inhibitoren des MAP-Kinase Signalweges diskutiert. Falls diese Therapiestrategien in Erwägung gezogen werden, sollte dies mit dem zuständigen Referenzzentrum diskutiert werden. Zudem sollten alle Kinder und Jugendliche mit LCH in laufende Register oder Studien eingeschlossen werden.

Abstract

The current standard therapy for children and adolescents with newly diagnosed Langerhans cell histiocytosis (LCH) is based on the two drugs prednisone and vinblastine. In patients with insufficient treatment response or disease relapse, the choice of second-line treatment depends on risk organ involvement (liver, spleen, and hematopoietic system). This article will give an overview of current data concerning therapeutic options in the different settings of children and adolescents with LCH. Due to limited evidence, these strategies have not been described in detail in the updated guidelines on pediatric LCH. In addition, the use of targeted therapy such as MAP-kinase inhibitors will be discussed. The reference center for LCH should be contacted if therapeutic options beyond the standard regimen are considered for treatment. All children and adolescents with LCH should be enrolled in registries or prospective studies.

Schlüsselwörter

Langerhanszell Histiozytose - Kind - Therapiestrategie - Stamzelltransplantation - zielgerichtete Therapie

Key words

Langerhans cell histiocytosis - child - therapeutic options - hematopoietic cell transplantation - targeted therapy


Publication History

Article published online:
06 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Lehrnbecher T, Ahlmann M, Albert MH. et al. Aktualisierte AWMF Leitlinie zur Diagnostik und Therapie der Langerhanszell Histiozytose (LCH) im Kindes- und Jugendalter. Klin Padiatr (im Druck)..
    PubMed
  • 2 Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). S1-Leitlinie Langerhanszell-Histiozytose (LCH) im Kindes- und Jugendalter. Version 8.0 (Stand 30.4.2023). AWMF online: https://register.awmf.org/assets/guidelines/025-015l_S1_Langerhanszell-Histiozytose-LCH-Kinder-Jugendliche_2023-05.pdf [aufgerufen 21. Juni, 2023].
    PubMed
  • 3 Gadner H, Heitger A, Grois N. et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol 1994; 23: 72-80
    CrossrefPubMedSearch in Google Scholar
  • 4 Minkov M, Grois N, Heitger A. et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr 2000; 212: 139-144
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Gadner H, Grois N, Arico M. et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 2001; 138: 728-734
    CrossrefPubMedSearch in Google Scholar
  • 6 Gadner H, Grois N, Potschger U. et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008; 111: 2556-2562
    CrossrefPubMedSearch in Google Scholar
  • 7 Gadner H, Minkov M, Grois N. et al. Therapy prolongation improves outcome in multi-system Langerhans cell histiocytosis. Blood. 2013; 121: 5006-5014
    CrossrefPubMedSearch in Google Scholar
  • 8 Grois N, Potschger U, Prosch H. et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 46: 228-233
    CrossrefPubMedSearch in Google Scholar
  • 9 Egeler RM, de Kraker J, Voute PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol 1993; 21: 265-270
    CrossrefPubMedSearch in Google Scholar
  • 10 De Benedittis D, Mohamed S, Rizzo L. et al. Indomethacin is an effective treatment in adults and children with bone Langerhans cell histiocytosis (LCH). Br J Haematol 2020; 191: e109-e113
    CrossrefPubMedSearch in Google Scholar
  • 11 Elomaa I, Blomqvist C, Porkka L. et al. Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone. J Intern Med 1989; 225: 59-61
    CrossrefPubMedSearch in Google Scholar
  • 12 Chellapandian D, Makras P, Kaltsas G. et al. Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series. Mediterr J Hematol Infect Dis 2016; 8: e2016033
    CrossrefPubMedSearch in Google Scholar
  • 13 Kudo K, Tanaka T, Kobayashi A. et al. Zoledronic acid for relapsed Langerhans cell histiocytosis with isolated skull bone lesion. Pediatr Int 2019; 61: 315-317
    CrossrefPubMedSearch in Google Scholar
  • 14 Morimoto A, Shioda Y, Imamura T. et al. Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan. Pediatr Blood Cancer 2011; 56: 110-115
    CrossrefPubMedSearch in Google Scholar
  • 15 Arico M, Colella R, Conter V. et al. Cyclosporine therapy for refractory Langerhans cell histiocytosis. Med Pediatr Oncol 1995; 25: 12-16
    CrossrefPubMedSearch in Google Scholar
  • 16 Minkov M, Grois N, Broadbent V. et al. Cyclosporine A therapy for multisystem langerhans cell histiocytosis. Med Pediatr Oncol 1999; 33: 482-485
    CrossrefPubMedSearch in Google Scholar
  • 17 Culic S, Jakobson A, Culic V. et al. Etoposide as the basic and interferon-alpha as the maintenance therapy for Langerhans cell histiocytosis: a RTC. Pediatr Hematol Oncol 2001; 18: 291-294
    CrossrefPubMedSearch in Google Scholar
  • 18 Barkaoui MA, Queheille E, Aladjidi N. et al. Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment. Br J Haematol 2020; 191: 825-834
    CrossrefPubMedSearch in Google Scholar
  • 19 Weitzman S, Braier J, Donadieu J. et al. 2’-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the histiocyte society. Pediatr Blood Cancer 2009; 53: 1271-1276
    CrossrefPubMedSearch in Google Scholar
  • 20 Irie M, Nakano T, Katayama S. et al. Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis. Cancer Rep (Hoboken) 2022; 5: e1579
    CrossrefPubMedSearch in Google Scholar
  • 21 Bernard F, Thomas C, Bertrand Y. et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41: 2682-2689
    CrossrefPubMedSearch in Google Scholar
  • 22 Donadieu J, Bernard F, van Noesel M. et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015; 126: 1415-1423
    CrossrefPubMedSearch in Google Scholar
  • 23 Simko SJ, Tran HD, Jones J. et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer 2014; 61: 479-487
    CrossrefPubMedSearch in Google Scholar
  • 24 Kudo K, Maeda M, Suzuki N. et al. Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis. Int J Hematol 2020; 111: 137-148
    CrossrefPubMedSearch in Google Scholar
  • 25 Veys PA, Nanduri V, Baker KS. et al. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol 2015; 169: 711-718
    CrossrefPubMedSearch in Google Scholar
  • 26 Heritier S, Emile JF, Helias-Rodzewicz Z. et al. Progress towards molecular-based management of childhood Langerhans cell histiocytosis. Arch Pediatr 2019; 26: 301-307
    CrossrefPubMedSearch in Google Scholar
  • 27 Pearson AD, Allen C, Fangusaro J. et al. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer 2022; 177: 120-142
    CrossrefPubMedSearch in Google Scholar
  • 28 Donadieu J, Larabi IA, Tardieu M. et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol 2019; 37: 2857-2865
    CrossrefPubMedSearch in Google Scholar
  • 29 Evseev D, Kalinina I, Raykina E. et al. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA. Int J Hematol 2021; 114: 725-734
    CrossrefPubMedSearch in Google Scholar
  • 30 Yang Y, Wang D, Cui L. et al. Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis. Cancer Res Treat 2021; 53: 261-269
    CrossrefPubMedSearch in Google Scholar
  • 31 Eckstein OS, Visser J, Rodriguez-Galindo C. et al. Clinical responses and persistent BRAF V600E(+) blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019; 133: 1691-1694
    CrossrefPubMedSearch in Google Scholar
  • 32 Imashuku S, Fujita N, Shioda Y. et al. Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease. Int J Hematol 2015; 101: 191-197
    CrossrefPubMedSearch in Google Scholar
  • 33 Allen CE, Flores R, Rauch R. et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer 2010; 54: 416-423
    CrossrefPubMedSearch in Google Scholar
  • 34 Cohen Aubart F, Idbaih A, Emile JF. et al. Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro Oncol 2021; 23: 1433-1446
    CrossrefPubMedSearch in Google Scholar
  • 35 Henter JI, Kvedaraite E, Martin Munoz D. et al. Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. Br J Haematol 2022; 196: 248-254
    CrossrefPubMedSearch in Google Scholar